Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Retifanlimab by Incyte for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Retifanlimab is under clinical development by Incyte and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...
Retifanlimab by Incyte for Non-Small Cell Lung Cancer: Likelihood of Approval
Retifanlimab is under clinical development by Incyte and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...
Retifanlimab by Incyte for Endometrial Cancer: Likelihood of Approval
Retifanlimab is under clinical development by Incyte and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
Retifanlimab by Incyte for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Retifanlimab is under clinical development by Incyte and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to...
Retifanlimab by Incyte for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Retifanlimab is under clinical development by Incyte and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma....
Retifanlimab by Incyte for Glioblastoma Multiforme (GBM): Likelihood of Approval
Retifanlimab is under clinical development by Incyte and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
Retifanlimab by Incyte for Sarcomas: Likelihood of Approval
Retifanlimab is under clinical development by Incyte and currently in Phase I for Sarcomas. According to GlobalData, Phase I drugs...
Retifanlimab by Incyte for Cervical Cancer: Likelihood of Approval
Retifanlimab is under clinical development by Incyte and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...